Risk of Seizure Recurrence Due to Autoimmune Encephalitis With NMDAR, LGI1, CASPR2, and GABABR Antibodies: Implications for Return to Driving.

MLA

Rada, Anna, et al. “Risk of Seizure Recurrence Due to Autoimmune Encephalitis With NMDAR, LGI1, CASPR2, and GABABR Antibodies: Implications for Return to Driving.” Neurology® Neuroimmunology & Neuroinflammation, vol. 11, no. 4, July 2024, pp. 1–12. EBSCOhost, https://doi.org/10.1212/NXI.0000000000200225.

APA

Rada, A., Hagemann, A., Poulsen, C. A., Baumgartner, T., Berki, T., Blaabjerg, M., Brenner, J., Britton, J. W., Christiana, A., Ciano-Petersen, N. L., Crijnen, Y., Elišák, M., Farina, A., Friedman, A. R., Hayden, Z., Hébert, J., Holtkamp, M., Zhen Hong, Honnorat, J., & Ilyas-Feldmann, M. (2024). Risk of Seizure Recurrence Due to Autoimmune Encephalitis With NMDAR, LGI1, CASPR2, and GABABR Antibodies: Implications for Return to Driving. Neurology® Neuroimmunology & Neuroinflammation, 11(4), 1–12. https://doi.org/10.1212/NXI.0000000000200225

Chicago

Rada, Anna, Anne Hagemann, Charlotte Aaberg Poulsen, Tobias Baumgartner, Timea Berki, Morten Blaabjerg, Juliette Brenner, et al. 2024. “Risk of Seizure Recurrence Due to Autoimmune Encephalitis With NMDAR, LGI1, CASPR2, and GABABR Antibodies: Implications for Return to Driving.” Neurology® Neuroimmunology & Neuroinflammation 11 (4): 1–12. doi:10.1212/NXI.0000000000200225.